Sanofi (SNY) Net Margin (2009 - 2026)

Sanofi (SNY) posted Net Margin of 56.37% for Q2 2026, down 467.02% sequentially from 15.36% in Q1 2026, and down 9579.0% YoY from 0.59% in Q2 2025.

Sanofi (SNY) Net Margin (2009 - 2026) Analysis & Trends

Sanofi has reported Net Margin for 18 years, with the latest figure at 56.37% in Q2 2026.

Quarterly Net Margin fell 9579.0% year-over-year to 56.37% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 6.23% (down 3019.0% YoY) and the FY2025 annual result came in at 17.91%, up 437.0% from the prior year.
Net Margin fell to 56.37% in Q2 2026 per SNY's latest filing, from 15.36% in the prior quarter.
Over five years, Net Margin peaked at 77.02% in Q4 2025 and troughed at 56.37% in Q2 2026.
A 5-year average of 16.4% and a median of 16.47% in 2022 frame the typical range for Net Margin.
The sharpest annual moves came in 2025 and 2026: Net Margin jumped 6927 bps in 2025, then sank 9579 bps in 2026.
Over 5 years, Net Margin stood at 16.3% in 2022, then tumbled by 109 bps to 1.47% in 2023, then surged by 628 bps to 7.76% in 2024, then soared by 893 bps to 77.02% in 2025, then tumbled by 173 bps to 56.37% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 56.37%, 15.36%, and 77.02% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	21.86%
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	21.28%
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-8.05%
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	22.65%
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	16.30%
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	23.62%
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-134.51%
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-1.58%
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	5.17%
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	2.96%

Download Data